Pricing, reimbursement and access
Refine Search
Pharmaceutical
The US Department of Health and Human Services (HHS)—through the Centers for Medicare and Medicaid Services (CMS)—has announced that some Medicare enrollees will pay less for 64 drugs available through Medicare Part B. 27 June 2024
Biotechnology
The UK’s health technology assessor has changed its tune regarding CSL Behring’s Hemgenix (etranacogene dezaparvovec), recommending the product for use in England and Wales. 27 June 2024
Pharmaceutical
London-based pharma major GSK—one of the UK’s flagship companies—has suffered a galling defeat on home soil to US rival Pfizer. 25 June 2024
Biotechnology
First treatment to address underlying pathophysiology of XLH backed by NICE 21 June 2024
Pharmaceutical
NICE recommends Eladynos for treating osteoporosis 21 June 2024
Biotechnology
Sanofi to appeal NICE's final draft guidance for Sarclisa 20 June 2024
Pharmaceutical
NICE’s decision to not re-appraise Spravato “gravely concerning,” says J&J 13 June 2024
Pharmaceutical
US Senator Bernie Sanders, chairman of the Senate Committee on Health, Education, Labor and Pensions (HELP), has announced that members will vote next week on w 12 June 2024
Pharmaceutical
Russia cutting centralized state purchases of anti-HIV drugs 12 June 2024
Biosimilars
Influx of biosimilar set to see significant market growth 5 June 2024
Pharmaceutical
Circuit sides with manufacturers in latest 340B contract pharmacy case 1 June 2024
Biosimilars
IGBA’s CEO Advisory Committee advances strategic focus on access to medicines 29 May 2024
Pharmaceutical
France remains the European “leader” in general and pharma levies 28 May 2024
Generics
UK-based Alliance Pharma (AIM: APH) has successfully appealed against a Competition and Markets Authority (CMA) ruling that had found the company guilty of brea 24 May 2024
Pharmaceutical
The US National Institutes of Health (NIH) has issued a first-of-its-kind draft policy proposal to promote equal access to products stemming from NIH-owned inve 23 May 2024
Pharmaceutical
A US Food and Drug Administration (FDA) panel will consider Lykos Therapeutics’ filing for midomafetamine capsules (MDMA) as a therapy-assisted treatment for po 15 May 2024
Biotechnology
US medicines spending grew 2.5% in 2023, says IQVIA Institute 15 May 2024
Pharmaceutical
Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s (NOVO: N) bid to become the GLP-1 company of choice for payers and prescribers. 15 May 2024
Pharmaceutical
The top most asked questions about Ozempic 14 May 2024
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze